[{"orgOrder":0,"company":"Grifols International","sponsor":"Aradigm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Grifols International","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Grifols International \/ Grifols","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Grifols"},{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Anti-SARS-CoV-2 hyperimmune globulin therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ BARDA"},{"orgOrder":0,"company":"Grifols International","sponsor":"Soleo Health","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Immune globulin human-klhw","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grifols International \/ Grifols","highestDevelopmentStatusID":"12","companyTruncated":"Grifols International \/ Grifols"},{"orgOrder":0,"company":"Grifols International","sponsor":"Savara","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ciprofloxacin","moa":"DNA gyrase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Grifols International \/ Savara","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Savara"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anti-SARS-CoV-2 hyperimmune globulin therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Rigel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Immunology","graph2":"Approved","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Grifols International \/ Grifols S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Grifols International \/ Grifols S.A."},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Perflutren","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Alkahest","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Acquisition","leadProduct":"Plasma-based therapies","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Grifols International","amount2":0.14999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"","sponsorNew":"Grifols International \/ Grifols","highestDevelopmentStatusID":"2","companyTruncated":"Grifols International \/ Grifols"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Hyperimmune globulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Anti-SARS-CoV-2 polyclonal antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"GigaGen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"GIGA-2050","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Grifols","highestDevelopmentStatusID":"6","companyTruncated":"Grifols International \/ Grifols"},{"orgOrder":0,"company":"Grifols International","sponsor":"Alkahest","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"GRF6021","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Grifols International \/ Grifols","highestDevelopmentStatusID":"8","companyTruncated":"Grifols International \/ Grifols"},{"orgOrder":0,"company":"Grifols International","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Hyperimmune immunoglobulin","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Grifols International \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ National Institutes of Health"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"GIGA-2050","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Tianjin Tiancheng Pharma. Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"BT524","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":1.28,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":1.28,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Grifols","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Grifols"},{"orgOrder":0,"company":"Grifols International","sponsor":"VCN Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Gemcitabine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Grifols International","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Intratumoral","sponsorNew":"Grifols International \/ Grifols","highestDevelopmentStatusID":"6","companyTruncated":"Grifols International \/ Grifols"},{"orgOrder":0,"company":"Grifols International","sponsor":"Endpoint Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Grifols International","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Grifols International \/ Endpoint Health","highestDevelopmentStatusID":"4","companyTruncated":"Grifols International \/ Endpoint Health"},{"orgOrder":0,"company":"Grifols International","sponsor":"Selagine","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"SLG-100","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Grifols International \/ Grifols International","highestDevelopmentStatusID":"1","companyTruncated":"Grifols International \/ Grifols International"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"SPAIN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Albumin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"BT524","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SPAIN","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Immune Globulin, Human","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Grifols International \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Grifols International \/ Not Applicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"SPAIN","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"OSIG-based Therapy","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Grifols International \/ BARDA","highestDevelopmentStatusID":"12","companyTruncated":"Grifols International \/ BARDA"}]

Find Clinical Drug Pipeline Developments & Deals by Grifols International

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : The partnership aims to test investigational ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sulfur mustard exposure.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 22, 2024

                          Lead Product(s) : OSIG-based Therapy

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : BARDA

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Xembify is the first and only 20% subcutaneous immunoglobulin (SCIg) with FDA-approved dosing for treatment of primary humoral immunodeficiency in patients 2 years of age and older.

                          Brand Name : Xembify

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 30, 2024

                          Lead Product(s) : Immune Globulin, Human

                          Therapeutic Area : Immunology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : BT524 is a fibrinogen concentrate which acts as as fibrinogen stimulant. It is being developed for the treatment of acquired fibrinogen deficiency (AFD).

                          Brand Name : BT524

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 14, 2024

                          Lead Product(s) : BT524

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : PROLASTIN®-C is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI.

                          Brand Name : Prolastin-C

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 15, 2023

                          Lead Product(s) : Human Alpha1-Proteinase Inhibitor

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Albutein® (albumin-human injection) is an abundant protein in plasma which has antioxidant and anti-inflammatory properties, and is being investigated for the treatment of decompensated Cirrhosis.

                          Brand Name : Albutein

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 18, 2023

                          Lead Product(s) : Human Albumin

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : PROLASTIN®-C is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI.

                          Brand Name : Prolastin-C

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 13, 2023

                          Lead Product(s) : Human Alpha1-Proteinase Inhibitor

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : PROLASTIN®-C is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI.

                          Brand Name : Prolastin-C

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 13, 2023

                          Lead Product(s) : Human Alpha1-Proteinase Inhibitor

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : Grifols will develop and commercialise immunoglobulin eye drops, SLG-100, for dry eye disease. An immunoglobulin eye drop is a biologic drug that contains naturally occurring functional antibodies generated from human plasma collected from thousands of h...

                          Brand Name : SLG-100

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 06, 2023

                          Lead Product(s) : SLG-100

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Recipient : Selagine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of Antithrombin III (AT-III), a plasma protein that treats patients with blood clotting issues.

                          Brand Name : AT-III

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 24, 2022

                          Lead Product(s) : Antithrombin III

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Endpoint Health

                          Deal Size : $25.0 million

                          Deal Type : Collaboration

                          blank

                          10

                          Antibody Engineering
                          Not Confirmed
                          Antibody Engineering
                          Not Confirmed

                          Details : VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional pat...

                          Brand Name : VCN-01

                          Molecule Type : Large molecule

                          Upfront Cash : $4.7 million

                          December 14, 2021

                          Lead Product(s) : VCN-01,Gemcitabine,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : VCN Biosciences

                          Deal Size : $77.4 million

                          Deal Type : Acquisition

                          blank